{"doc_id": "si-2025-0229-reg-1", "parent_doc_id": "si-2025-0229", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "1. These Regulations may be cited as the Misuse of Drugs (Prescription and", "text_raw": "1. These Regulations may be cited as the Misuse of Drugs (Prescription and \nControl of Supply of Cannabis for Medical Use) (Amendment) Regulations", "text_norm": "1 regulation may cited misuse drug (prescription control supply cannabis medical use) (amendment) regulation", "start_char": 673, "end_char": 821, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
{"doc_id": "si-2025-0229-reg-2025", "parent_doc_id": "si-2025-0229", "section_id": "reg-2025", "section_label": "Regulation 2025.", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "Definitions", "text_raw": "2025. \n\nDefinitions", "text_norm": "2025 definition", "start_char": 821, "end_char": 843, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
{"doc_id": "si-2025-0229-reg-2", "parent_doc_id": "si-2025-0229", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "In these Regulations –", "text_raw": "2. \n\nIn these Regulations – \n\n“Principal Regulations” means the Misuse of Drugs (Prescription and Control of \nSupply of Cannabis for Medical Use) Regulations 2019 (S.I. No. 262 of 2019), \nas amended by the Misuse of Drugs (Prescription and Control of Supply of \nCannabis for Medical Use) (Amendment) Regulations 2019 (S.I. No. 583 of \n2019), the Misuse of Drugs (Prescription and Control of Supply of Cannabis for \nMedical Use) (Amendment) Regulations 2019 (S.I. No. 649 of 2019), the Misuse \nof Drugs (Prescription and Control of Supply of Cannabis for Medical Use) \n(Amendment) Regulations 2020 (S.I. No. 505 of 2020), the Misuse of Drugs \n(Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) \nRegulations 2021 (S.I. No. 557 of 2021), the Misuse of Drugs (Prescription and \nControl of Supply of Cannabis for Medical Use) (Amendment) Regulations 2022 \n(S.I. No. 237 of 2022), the Misuse of Drugs (Prescription and Control of Supply \nof Cannabis for Medical Use) (Amendment) Regulations 2023 (S.I. No. 5 of \n2023) and the Misuse of Drugs (Prescription and Control of Supply of Cannabis \nfor Medical Use) (Amendment) (No. 2) Regulations 2023 (S.I. No. 200 of 2023). \n\nAmending the Principal Regulations", "text_norm": "2 regulation - principal regulation mean misuse drug (prescription control supply cannabis medical use) regulation 2019 (s.i no 262 2019) amended misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2019 (s.i no 583 2019) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2019 (s.i no 649 2019) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2020 (s.i no 505 2020) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2021 (s.i no 557 2021) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2022 (s.i no 237 2022) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2023 (s.i no 5 2023) misuse drug (prescription control supply cannabis medical use) (amendment) (no 2) regulation 2023 (s.i no 200 2023) amending principal regulation", "start_char": 843, "end_char": 2071, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
{"doc_id": "si-2025-0229-reg-3", "parent_doc_id": "si-2025-0229", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "3. The Principal Regulations are amended by substituting for Schedule 1", "text_raw": "3. The Principal Regulations are amended by substituting for Schedule 1 \n\nthe following: \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 3rd June, 2025. \n\n \n \n \n \n \n \n \n\f“SCHEDULE 1 \n\nSpecified Controlled Drugs \n\n[229] 3 \n\nRegulation 2 \n\nName of \nCannabis \nproduct or \npreparation \nand brand \nname \n\nDosage form Concentration of THC \n\n(percentage, \nweight/weight or \nweight/volume) \n\nName of \nmanufacturer \n\nAurora High \nCBD Oil Drops \n\nOral solution Less than 3% w/v \n\n(<30mg/ml) \n\nThis product also \ncontains cannabidiol \n(CBD) 60% w/v \n(600mg/ml) \n\nAurora Cannabis \nEnterprises Inc., \n4439 Township \nRoad 304, \nCremona, \n\nAlberta, Canada, \nT0M 0R0 \n\nCannEpil ™ \n\nOral solution 0.5% w/v (5mg/ml) \n\nMGC \n\nThis product also \ncontains cannabidiol \n(CBD) 10% w/v \n(100mg/ml) \n\nOral solution 1% w/v (10mg/ml) \n\nThis product also \ncontains cannabidiol \n(CBD) 1% w/v \n(10mg/ml) \n\nTilray Oral \nSolution \nTHC10:CBD10 \n(25ml) \n\nPharmaceuticals \nd.o.o., Kamniška \nulica 29, 1000, \nLjubljana, \nSlovenia \n\nTilray Portugal \nUnipessoal Lda., \nZona Industrial de \nCantanhede, \n\nLote 121, \nCantanhede, \n\n3060-197, \nPortugal \n\n \n \n \n\f4 [229] \n\nAurora \nSedamen \nSoftgels \n\nCapsules \n\n5mg/capsule \n\nThis product also \ncontains cannabidiol \n(CBD) less than", "text_norm": "3 principal regulation amended substituting schedule 1 following notice making statutory instrument published iris oifigiuil 3rd june 2025 schedule 1 specified controlled drug 229 3 regulation 2 name cannabis product preparation brand name dosage form concentration thc (percentage weight weight weight volume) name manufacturer aurora high cbd oil drop oral solution le 3 w v ( 30mg ml) product also contains cannabidiol (cbd) 60 w v (600mg ml) aurora cannabis enterprise inc 4439 township road 304 cremona alberta canada t0m 0r0 cannepil (tm) oral solution 0.5 w v (5mg ml) mgc product also contains cannabidiol (cbd) 10 w v (100mg ml) oral solution 1 w v (10mg ml) product also contains cannabidiol (cbd) 1 w v (10mg ml) tilray oral solution thc10 cbd10 (25ml) pharmaceutical d.o.o kamniska ulica 29 1000 ljubljana slovenia tilray portugal unipessoal lda zona industrial de cantanhede lote 121 cantanhede 3060-197 portugal 4 229 aurora sedamen softgels capsule 5mg capsule product also contains cannabidiol (cbd) le", "start_char": 2071, "end_char": 3352, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
{"doc_id": "si-2025-0229-reg-0", "parent_doc_id": "si-2025-0229", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "0.2mg/capsule", "text_raw": "0.2mg/capsule \n\nOleo \nBedrobinol \n\nDried flower 13.5% w/w (135mg/g) \n\nThis product also \ncontains cannabidiol \n(CBD) less than 1.0% \nw/w (less than 10mg/g) \n\nOleo Bedrocan Dried flower 22% w/w (220mg/g) \n\nThis product also \ncontains cannabidiol \n(CBD) less than 1.0% \nw/w (less than 10mg/g) \n\nAlthea \nCBD12:THC10 \n(50ml) \n\nOil \n\n1% w/v THC (10mg/ml) \n\nThis product also \ncontains 1.25% w/v \n(12.5mg/ml) cannabidiol \n(CBD) \n\nAurora Cannabis \nEnterprises Inc. \n4250 14th \nAvenue, \nMarkham, \nOntario, Canada \nL3R 0J3 \n\nBureau voor \nMedicinale \nCannabis \n\nPostbus 16114 \n2500 \n\nBC DEN HAAG \nThe Netherlands \n\nBureau voor \nMedicinale \nCannabis \n\nPostbus 16114 \n2500 \n\nBC DEN HAAG \nThe Netherlands \n\nTasmanian \nAlkaloids pty Ltd \nT/A Extractas \nBioscience, \nWestbury, \nTasmania, \nAustralia 7303 \n\n \n \n \n \n \n\fOleo Genetics \n10:10 \n\nOil (oral \nsolution) \n\n1% w/v (10mg/ml) \n\nThis product also \ncontains cannabidiol \n(CBD) 1% w/v \n(10mg/ml) \n\nOleo Genetics \n25:1 \n\nOil (oral \nsolution)", "text_norm": "0.2mg capsule oleo bedrobinol dried flower 13.5 w w (135mg g) product also contains cannabidiol (cbd) le 1.0 w w (less 10mg g) oleo bedrocan dried flower 22 w w (220mg g) product also contains cannabidiol (cbd) le 1.0 w w (less 10mg g) althea cbd12 thc10 (50ml) oil 1 w v thc (10mg ml) product also contains 1.25 w v (12.5mg ml) cannabidiol (cbd) aurora cannabis enterprise inc 4250 14th avenue markham ontario canada l3r 0j3 bureau voor medicinale cannabis postbus 16114 2500 bc den haag netherlands bureau voor medicinale cannabis postbus 16114 2500 bc den haag netherlands tasmanian alkaloid pty ltd extractas bioscience westbury tasmania australia 7303 oleo genetics 10 10 oil (oral solution) 1 w v (10mg ml) product also contains cannabidiol (cbd) 1 w v (10mg ml) oleo genetics 25 1 oil (oral solution)", "start_char": 3352, "end_char": 4331, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
{"doc_id": "si-2025-0229-reg-2", "parent_doc_id": "si-2025-0229", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "2.5% w/v (25mg/ml)", "text_raw": "2.5% w/v (25mg/ml) \n\nThis product also \ncontains cannabidiol \n(CBD) <0.1% w/v \n(<1mg/ml) \n\nAlthea \n\nOil \n\n2% w/v THC (20mg/ml) \n\nTHC20:CBD1 \n\n(50ml) \n\nThis product also \ncontains <0.1% w/v \n(<0.1mg/ml) cannabidiol \n(CBD) \n\nDynabis \n25THC:25CBD \n\nOil (oral \nsolution)", "text_norm": "2.5 w v (25mg ml) product also contains cannabidiol (cbd) 0.1 w v ( 1mg ml) althea oil 2 w v thc (20mg ml) thc20 cbd1 (50ml) product also contains 0.1 w v ( 0.1mg ml) cannabidiol (cbd) dynabis 25thc 25cbd oil (oral solution)", "start_char": 4331, "end_char": 4600, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
{"doc_id": "si-2025-0229-reg-2", "parent_doc_id": "si-2025-0229", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "2.5% w/v THC", "text_raw": "2.5% w/v THC \n\n(25mg/ml) \n\nThis product also \ncontains cannabidiol \n(CBD) 2.5% w/v \n(25mg/ml) \n\n[229] 5 \n\nADREX Pharma \nGmbH \nFirmungstrabe 4 \n56068 Koblenz \nGermany \n\nADREX Pharma \nGmbH \nFirmungstrabe 4 \n\n56068 Koblenz \n\nGermany \n\nTasmanian \nAlkaloids pty Ltd \nT/A Extractas \nBioscience, \nWestbury, \nTasmania, \nAustralia 7303 \n\nNYSK Holdings, \nIndustriska Zona \nKjojlija, \n\nPatrovec, \n\nSkopje MK, \n\n1000, North \nMacedonia \n\n \n \n \n \n \n \n\f6 [229] \n\nGIVEN under my Official Seal, \n\n29 May, 2025. \n\nJENNIFER CARROLL MACNEILL, \n\nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n\f[229] 7", "text_norm": "2.5 w v thc (25mg ml) product also contains cannabidiol (cbd) 2.5 w v (25mg ml) 229 5 adrex pharma gmbh firmungstrabe 4 56068 koblenz germany adrex pharma gmbh firmungstrabe 4 56068 koblenz germany tasmanian alkaloid pty ltd extractas bioscience westbury tasmania australia 7303 nysk holding industriska zona kjojlija patrovec skopje mk 1000 north macedonia 6 229 given official seal 29 may 2025 jennifer carroll macneill minister health 229 7", "start_char": 4600, "end_char": 5179, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
{"doc_id": "si-2025-0229-explanatory-note", "parent_doc_id": "si-2025-0229", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThe purpose of these Regulations is to update and replace the current Schedule \n1, in the Misuse of Drugs (Prescription and Control of Supply of Cannabis for \nMedical Use) Regulations 2019 (as amended) (“the Principal Regulations”), in \norder to include additional cannabis products or preparations for medical use as \n“specified controlled drugs”. \n\nThe purpose of the Principal Regulations is to allow additional cannabis products \nor preparations for medical use to be prescribed and supplied under certain \ncircumstances for the treatment of persons with certain medical conditions under \nthe care of a medical consultant. \n\nThese Regulations may be cited as the Misuse of Drugs (Prescription and \nControl of Supply of Cannabis for Medical Use) (Amendment) Regulations", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) purpose regulation update replace current schedule 1 misuse drug (prescription control supply cannabis medical use) regulation 2019 (as amended) ( principal regulation ) order include additional cannabis product preparation medical use specified controlled drug  purpose principal regulation allow additional cannabis product preparation medical use prescribed supplied certain circumstance treatment person certain medical condition care medical consultant regulation may cited misuse drug (prescription control supply cannabis medical use) (amendment) regulation", "start_char": 5179, "end_char": 6068, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
{"doc_id": "si-2025-0229-reg-2025", "parent_doc_id": "si-2025-0229", "section_id": "reg-2025", "section_label": "Regulation 2025.", "si_number": "S.I. No. 229 of 2025", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control of", "year": 2025, "heading": "8 [229]", "text_raw": "2025. \n\n \n \n \n \n \n\f8 [229] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-581) 30. 6/25. Propylon.", "text_norm": "2025 8 229 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-581) 30 6 25 propylon", "start_char": 6068, "end_char": 6580, "source_path": "downloads\\2025\\2025_0229.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6315f7b4e5e8ccf9ce71a009dd4d2f9a00d72ed8406936cd72ab11205060bc00", "cross_refs": []}
